IMPORTANCE Thyrotoxic periodic paralysis (TPP) is a potentially lethal complication of hyperthyroidism. However, only 1 specific susceptibility locus for TPP has been identified. Additional genetic determinants should be detected so that a prediction model can be constructed.
Introduction
Thyrotoxic periodic paralysis (TPP) is a potentially life-threatening complication of hyperthyroidism characterized by symptoms that include muscle weakness or paralysis, acute serum hypokalemia, and thyrotoxicosis. 1 The condition can occur in any ethnicity 2, 3 but predominantly affects Asian populations. 1, 4 Incidence of TPP in Chinese and Japanese patients with thyrotoxicosis is 1.8% 5 and
1.9%, 6 respectively. Despite a higher incidence of thyrotoxicosis in women (the female to male ratio is between 4:1 and 10:1), TPP predominantly affects men (the male to female ratio is between 22:1 and 76:1). 3, 4 In Chinese populations, TPP occurs in 13% of male and 0.17% of female patients with thyrotoxicosis. 3 Based on the higher prevalence of TPP in Asian populations than in European populations, 1, 4 we hypothesize that Asian populations have a genetic predisposition to develop TPP.
The genetic pathogenesis of TPP remains unknown. Recently, a newly identified Kir channel, Kir2.6 (encoded by KCNJ18), has been reported to predispose patients with TPP to acute paralytic attacks. 7 Mutations of KCNJ18 in 10 of 30 patients (33%) with TPP from Brazil, the United States, and
France have been reported. 7 Kir2.6 loss-of-function mutations triggered a positive feed-forward cycle of hypokalemia leading to muscle inexcitability. 7 However, Kir2.6 mutations were rarely identified in individuals with TPP from Asian populations. 7, 8 Although 3 genome-wide association studies (GWAS) with small sample sizes showed that chromosome 17q24.3 near KCNJ2 was the susceptibility locus of TPP, the causal single-nucleotide polymorphism (SNP) in this region remains controversial. [9] [10] [11] Based on the missing heritability data and small samples in the previous findings and TPP attacks triggered by any form of hyperthyroidism, 12 we hypothesize that TPP could be a molecular subtype of hyperthyroidism with a different genetic susceptibility than that of Graves disease (GD).
Therefore, the present 2-stage GWAS was carried out in a total of 537 patients with TPP, 1519 patients with GD and no history of TPP, and 3249 healthy participants from the Chinese Han population. In this study, we identified novel TPP risk loci, especially 2 specific TPP loci, and distinguished patients with TPP from those with GD based on TPP-specific susceptibility genes.
Methods

Characteristics of Study Participants
In collaboration with hospitals in China, samples were obtained with local institutional review board 
GWAS Genotyping and Initial Quality Control
Samples from the TPP GWAS (158 patients with TPP and 803 controls) and GD GWAS (17 patients with TPP, 1519 patients with GD and no history of TPP, and 1516 controls) were genotyped using HumanOmniZhonghua-8 BeadChip and Human660-Quad BeadChip kits 13, 14 (Illumina, Inc), with GD and no history of TPP, and 2160 healthy controls were conducted using SNPTEST version 2 software (Oxford University Innovation) (eFigure 2 in the Supplement).
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Evaluation of Population Structure and Quantile-Quantile Plots
To evaluate the population structure in samples, principal component analysis (PCA) (eFigure 3A in the Supplement) and multidimensional scaling (eFigure 3B in the Supplement) analysis were performed by SmartPCA 16 and PLINK, 17 respectively. And the distribution of observed P values (on the -log 10 scale) of given SNPs were plotted against the theoretical distribution of expected P values to construct quantile-quantile plots (eFigure 4 in the Supplement).
Genotyping in the Replication Stage
For the replication study, 100 SNPs specifically associated with TPP in 71 chromosomal regions were selected and genotyped in the second cohort (362 patients with TPP, 1089 sex-matched controls) (eTable 1, eTable 2, and eFigure 5 in the Supplement) using TaqMan SNP Genotyping Assays (Applied Biosystems) on the EP1 platform (Fluidigm). To increase statistical power, we also genotyped 100
selected SNPs in the GWAS samples and 34 SNPs within 22 GD susceptibility chromosomal regions in the replication stage using the 7900HT Fast Real Time PCR System (Applied Biosystems) (eTable 3 in the Supplement).
Association Analyses in Replication and Combined Populations
For autosomal SNPs, we used the Cochran-Armitage trend test in the replication stage and the Cochran-Mantel-Haenszel stratification analysis in combined samples. 17 The difference among the studies was examined using the Breslow-Day test. 17 Age-and sex-adjusted odds ratios (ORs) were obtained by logistic regression analysis using PLINK. 17 Conditional logistic regression analysis was used to examine independent effects of individual SNPs using R statistics packages (R Project for Statistical Computing).
Prediction Models
We constructed the prediction model using the weighted genetic risk score (wGRS) 18 and 2 different markers. First, 3 independent TPP-specific SNPs in 3 chromosomal loci were used as the markers to construct the wGRS model. Then, a total of 11 independent SNPs in 8 chromosomal loci with replication stage P < .05, with combined analysis P < .0005 (Bonferroni-corrected significance in combined populations), and with TPP vs GD P < .05 were used as the markers to construct the wGRS model. The value of the weighted score was rescaled by dividing all values by the sum of the effect sizes and then multiplying by the total number of SNPs, thus obtaining the final weighted GRS. 18 Next, logistic regression was used to calculate the OR and P values for each wGRS and sex as a covariant. Subsequently, we generated the receiver operating characteristic (ROC) curves and calculated the area under the curve (AUC) and the sensitivity and specificity of each model to determine how well the models discriminated between the patients with GD and a history of TPP and the patients with GD and no history of TPP. We then categorized the risk scores as 4 different groups according to the mean wGRS and SD P values, and ORs and 95% confidence intervals were evaluated using group 1 as the reference.
Results
Characteristics of the Samples in This Study
A total of 2056 patients with GD and 3249 healthy participants were recruited from the Chinese Han population through collaboration with the hospitals in China ( Table 2) . Thus, hyperthyroidism relapse was probably higher in patients with TPP than in patients with GD without TPP after discontinuation of antithyroid drug (ATD) treatment.
Identification of TPP-Specific Susceptibility Loci
After the association analyses in the discovery stage (eTable 1 and eFigure 2 in the Supplement), we genotyped 100 TPP-specific SNPs (discovery stage for TPP vs control, P < 5 × 10 −4 and for TPP vs GD, P < .05), as well as 34 SNPs in 22 known GD susceptibility regions of 362 TPP cases and 1089 controls (eTable 2, eTable 3, and eFigure 5 in the Supplement). In the combined population, we found 3 loci (rs1352714 at 4q31.3, rs4947296 at 6p21.3, and rs312691 at 17q24.3) were unequivocally associated with TPP, with a genome-wide significance threshold of P = 5.0 × 10
, and 2 loci (rs5912838 at Xq21.1 and rs2186564 at 11q14.1) reached the Bonferroni-corrected significance rather than genome-wide significance ( Table 3 ). In 3 of 5 TPP susceptibility loci, SNPs showed significant difference between 533 patients with TPP and 1404 patients with GD and no history of TPP in our combined cohorts, suggesting they were TPP-specific risk loci (Table 3 ; eTable 2 in the Supplement). Using a liability threshold model, 6.8% of TPP heritability was associated with 5 TPP risk loci and 3.1% with 3 specific TPP susceptibility loci. For the 5 SNPs associated with GD in the previous study, the heterogeneity analysis was performed in the total of 533 patients with TPP and 5160 patients with GD.
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The was a novel, specific TPP susceptibility locus. rs2186564 is located in exon 4 of C11orf67, causing a Val92Met amino acid substitution ( Figure 1B) . Interestingly, a cluster of SNPs highly associated with rs2186564 in an approximately 577-kb linkage disequilibrium region at 11q14.1 was correlated with expression of C11orf67 and INTS4 in skeletal muscles, CD4 + T cells, and naive monocytes (eFigure 7 in the Supplement).
Among 3 specific TPP risk loci, the most significant associations were SNPs rs312691, rs312729, and rs623011 on 17q24.3 ( Figure 1C and Table 3 ). This finding confirmed previous reports that this region is associated with TPP. [9] [10] [11] Based on GWAS data, 12 tagSNPs, including rs312691, were selected and genotyped in a replication cohort for refining the association study ( Figure 1D ; eTable 7 in the Supplement). We found rs312691, rs7222503, or their highly associated SNPs were independent variants at 17q24.3 (OR, 2.02; 95% CI, 1.77-2.31; combined P = 6.08 × 10 −24 for rs312691 and OR, 1.79; 95% CI, 1.45-2.20; combined P = 6.17 × 10 −8 for rs7222503) ( Table 3 ; eTable 8 and eFigure 8 in the Supplement).
The risk SNP rs312691 was significant when comparing 533 patients with TPP and 1404 patients with GD and no history of TPP (OR, 2.08; 95% CI, 1.81-2.39; P = 7.02 × 10 −24 ) (Table 3) . Notably, the risk allele C frequency of rs312691 was higher in Chinese Han populations (46%) than in European 
TPP Susceptibility Genes Shared With Patients With GD and No History of TPP
In the previous genetic studies of GD, a total of 22 GD risk loci were identified. 13, 14, 19, 20 Given that the onset of TPP was contingent on the occurrence of thyrotoxicosis, we chose and genotyped 34 SNPs ) and 1 SNP at Xq21.1 met the Bonferroni-corrected significance rather than the genome-wide significance level in the combined population (Table 3 ; eTable 3 in the Supplement). Among the 2 genetic susceptibility chromosome loci shared between patients with TPP and patients with GD without TPP, the most statistically significant association was detected at rs4947296 close to C6orf15 (OR, 2.06; 95% CI, 
Prediction Models Used to Discriminate Between TPP and GD
The prediction wGRS model of all participants with GD containing 3 independent TPP-specific risk SNPs and 11 candidate TPP-specific SNPs had AUCs of 0.74 and 0.80, respectively (Figure 2A ).
Sensitivity and specificity of the prediction models were also evaluated, and the wGRS model containing 11 SNPs had higher sensitivity (82%) and less specificity (68%), causing a proportion of individuals with GD without TPP to be misclassified as having TPP (eTable 9 in the Supplement). The OR of each wGRS group increased in parallel with the level of TPP risk. As for the wGRS model approximately 16.27 to 18.76 times greater risk of developing TPP than those in group 1 ( Figure 2C ; eTable 9 in the Supplement).
Discussion
Using a 2-stage GWAS in 533 patients with TPP, 1404 patients with GD and no history of TPP, and 3249 healthy individuals, we identified 5 TPP risk loci, including 3 TPP-specific loci and 2 loci shared with GD. Three chromosomal regions (KCNJ2-CTD-2378E21.1 on 17q24.3, DCHS2 on 4q31.3, and HLA)
were unequivocally associated with TPP using a GWAS threshold of P = 5 × 10
, and 2 loci (C11orf67 on 11q14.1 and ITM2A on Xq21.1) met the Bonferroni-corrected significance rather than the GWAS criterion. Two of 3 specific TPP susceptibility loci were identified for the first time, to our knowledge, to be associated with TPP in the Chinese Han population. Identification of 3 TPP-specific susceptibility loci in this study provided evidence that TPP is a new GD molecular subtype with specific risk genes. The frequency of risk allele SNPs in 3 TPP-specific susceptibility loci in Chinese
Han populations was much higher than in European populations, which at least partially explains TPP predominance in Asian populations. The prediction model using wGRS and 11 candidate TPP-specific
SNPs had an AUC of 0.80.
Patients with TPP have episodes of paralysis only while they have thyrotoxicosis. Although any form of hyperthyroidism can cause TPP, most TPP occurs with GD. Patients with TPP are typically first diagnosed with periodic paralysis, 21, 22 and signs and symptoms of thyrotoxicosis in TPP may be subtle. In several previous studies, [22] [23] [24] only 10% to 30% of the patients showed symptomatic hyperthyroidism at presentation of episodes of TPP. No palpable goiter is found clinically in most patients. 24, 25 Hyperthyroidism in patients with TPP is often mild at TPP outset and, thus, risk of hyperthyroidism relapse should be lower after discontinuing ATD treatment. We found that the percentage of persistent TRAb positivity was significantly higher in patients with TPP than in those with GD and no history of TPP after drug or radioiodine treatment for more than 1 or 2 years. Because positive TRAb before discontinuing ATD is the best predictor of GD relapse, 26, 27 these findings indicate that TPP should not be treated by ATD. Indeed, 1 recent study 28 found that all 8 patients with TPP developed thyrotoxic relapse after ATD withdrawal, even if they were treated with ATD for 37.5 (range, 22-247) months. Moreover, patients with TPP who received lower sodium iodide I 131 levels had an unsatisfactory overall remission rate of 28.6%. 28, 29 Therefore, our data and other findings suggest that TPP, with specific symptoms and response to treatments caused by pathways that differ from that underlying GD, should not be treated by ATD, and a median or high dose of sodium iodide I 131 is necessary to rapidly control thyrotoxicosis.
Association of an SNP cluster at 17q24.3 with TPP has been established in previous studies [9] [10] [11] and confirmed here. rs312732 (risk allele A), a proxy of rs312691 (r 2 = 0.94) located in exon 3 of long intergenic noncoding RNA CTD-2378E21.1, correlated with KCNJ2 expression in C2C12 skeletal muscle cells. 11 By searching cis-eQTL data of skeletal muscle samples from the GTEx database, we found a cluster of SNPs highly associated with rs312691 that correlated with KCNJ2 expression. Risk allele C of rs312691 downregulated KCNJ2 expression compared with reference allele T. KCNJ2 mutations could lead to Andersen-Tawil syndrome, a disease characterized by periodic paralysis, cardiac arrhythmias, and dysmorphic features. 30 Moreover, thyrotoxicosis dramatically promoted periodic paralysis in a patient with Andersen-Tawil syndrome with a de novo c.G899C mutation in KCNJ2. 31 The second highest signal specifically associated with TPP was rs1352714, located in exon 13 of DCHS2 on 4q31.3, resulting in an Asn897Ser amino acid substitution. DCHS2, an atypical calcium-dependent cell-adhesion protein, regulates planar cell polarity, tissue size, and cell adhesion.
DCHS2 plays a role in controlling cartilage differentiation and polarity during craniofacial development 32 and is associated with neurofibrillary tangle progression, a neuropathological hallmark of Alzheimer disease due to intraneuronal aggregates of highly phosphorylated microtubule-associated protein tau. 33 Many SNPs in the DCHS2 region have been identified by GWAS to be associated with the age at onset of Alzheimer disease 34 or with human facial feature variants such as nose columella inclination.
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However, how DCHS2 variants are involved in TPP pathogenesis remains unknown.
Thyrotoxic periodic paralysis is a potentially lethal complication of hyperthyroidism and resolves when thyroid hormone levels are normalized. Therefore, predicting and identifying TPP in patients with hyperthyroidism is critical to prevent TPP episodes. However, no method to differentially diagnose TPP in hyperthyroidism patients without TPP has been identified before patients have muscle paralysis and hypokalemia episodes. With 3 independent SNPs in 3 specific TPP risk loci and 11 candidate TPP-specific SNPs as predictive markers, we established the prediction model to differentiate patients with TPP from those with GD. Notably, the prediction model containing 11 candidate TPP-specific SNPs with AUCs of 0.80 was usable to differentiate patients with TPP from those with GD. However, the genetic risk score analysis is probably not ready for clinical implementation if treatment decisions are to be based on the predictions.
Limitations
There are 4 main limitations in this study. First, the sample size of patients with TPP is not large enough to detect more TPP risk loci. Second, we did not perform the follow-up study for the patients with TPP recruited in our study. Third, we do not have a verification model for the prediction model.
Fourth, we did not test the patients with GD in resequencing substudy (eTable 10 in the Supplement).
Further extensive studies and larger samples will be required before definitive conclusions can be drawn.
Conclusions
In this study, we identified 4 novel TPP risk loci and confirmed 1 previous reported TPP locus. Of these, 3 loci were TPP-specific and 2 loci were shared with GD. The newly identified loci, along with other previously reported loci, demonstrate the growing complexity of the heritable contribution to TPP pathogenesis. A complete genetic architecture will be helpful to understand the pathophysiology of TPP.
The percentage of persistent TRAb positivity was higher in patients with TPP after 1 or 2 years of treatment than in patients with GD without TPP. Based on these specific TPP susceptibility loci as the predictive markers, we established the prediction model to differentiate patients with TPP from 
